Candace Mahan
Family · Center, TXNPI 1831635614
Payments from drug & device makers
Across 375 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$766
- Boehringer Ingelheim$744
- Novo Nordisk$724
- Lilly USA, LLC$568
- Pfizer$521
- plus $2K from 20 others
What the payments were for
- Food & beverage$6,35897%
- Education$2113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 58 | $1,336 |
| AbbVie(2 entities) | 51 | $766 |
| Boehringer Ingelheim | 46 | $744 |
| Novo Nordisk | 42 | $724 |
| Lilly USA, LLC | 44 | $568 |
| Pfizer | 30 | $521 |
| Bayer | 18 | $285 |
| Astellas Pharma US Inc | 11 | $281 |
| Otsuka America Pharmaceutical, Inc. | 11 | $246 |
| Amgen | 14 | $210 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $207 |
| GSK | 9 | $148 |
| Axsome Therapeutics, Inc. | 4 | $83 |
| Exact Sciences | 5 | $82 |
| Idorsia Pharmaceuticals US Inc | 5 | $68 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Antares Pharma, Inc. | 3 | $56 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $51 |
| Dexcom, Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Enterra Medical, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Alkermes, Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $13 |
| Vifor Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,569 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 95 | $133,329 |
| EliquisApixaban | 62 | $66,897 |
| JardianceEmpagliflozin | 53 | $58,702 |
| FarxigaDapagliflozin Propanediol | 45 | $56,965 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $29,656 |
| ProliaDenosumab | 12 | $21,081 |
| RexultiBrexpiprazole | 12 | $20,423 |
| XareltoRivaroxaban | 16 | $19,328 |
| TrulicityDulaglutide | 12 | $18,309 |
| LinzessLinaclotide | 13 | $15,102 |
| MyrbetriqMirabegron | 17 | $10,302 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $9,754 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,719 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $4,707 |
| Rosuvastatin Calcium | 325 | $3,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $724 | $133,32995 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,336 | $91,328102 claims |
| PfizerEliquis | $521 | $66,89762 claims |
| Boehringer IngelheimJardiance | $744 | $58,70253 claims |
| AmgenProlia | $210 | $21,08112 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $246 | $20,42312 claims |
| Lilly USA, LLCTrulicity | $568 | $18,30912 claims |
| AbbVieLinzess | $766 | $15,10213 claims |
| Astellas Pharma US IncMyrbetriq | $281 | $10,30217 claims |
| GSKAnoro Ellipta | $148 | $5,71912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Center
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.